



ASX Release

Quarterly Cash Flow Report and Trading Update

Quarter ended 30 September 2016

Melbourne, Australia; 31 October 2016: Jayex Healthcare Limited (ASX: JHL) (**Jayex** or **Company**), a leading e-health provider of integrated healthcare services delivery platforms, today released its Appendix 4C – Quarterly cash flow report for the quarter ended 30 September 2016 (the **Quarter**).

During the Quarter JHL's consolidated cash receipts amounted to over AUD\$2m and are AUD\$8.4m for the 9 months to 30 September 2016. The receipts have been adversely affected by the depreciation of the UK Pound, which is down over 16% against the Australian Dollar since Jan 1st 2016. Receipts derived from the UK represent approximately 80% of consolidated cash receipts.

Cash at bank over the quarter was relatively unchanged at \$1.659m.

Operationally the Company continues to deploy Appointuit (Patient Engagement) and the Enlighten Patient Flow Management Platform (kiosks, calling screens and wayfinding technologies) across the UK and Australia. The P2U platform continues to be developed in readiness for a planned market launch in 2017.

During the quarter and since the key operational highlights include:

- JHL was selected as the preferred tenderer to one of Australia's largest community health organisations that delivers services across multiple sites in Melbourne. The scope and roll out of the technology solution is expected to be delivered by the end of the year.
- JHL has recently concluded a successful patient arrival / check in / wayfinding trial with another major Melbourne Hospital Group and are currently in discussion around deployment of the technology solutions across applicable hospitals in the network. This negotiation is expected to be concluded in the coming months.
- JHL signed its first order to deploy the Enlighten Patient Flow Management platform in a New Zealand general practice and is well advanced with trials at a further 4 separate sites with the help of a large Primary Health Organisation (**PHO**). The trials, which includes tailoring the Enlighten Platform to assist Practices in meeting many of the Foundation Standards issued by The Royal New Zealand College of General Practitioners, are expected to be concluded prior to CY2017. There are approximately 1,000 Practices in New Zealand who are assisted by 32 PHO's and JHL is working closely with several of the largest PHO's to accelerate growth in this market. JHL is looking to finalise a Sales and Support Agreement with a major entity within the Primary Healthcare market, which will reduce the need for a dedicated sales and support team in the New Zealand market.

Commenting on the announcement Chairman Michael Boyd said “Whilst the recent successes of trials in hospitals and the expansions into New Zealand has taken time, it has not diminished the opportunity that was envisaged for the group. We will continue to focus on rolling out our technologies in the UK and Asia Pacific Regions and look forward to capturing more opportunities in the near future.”

Contacts for further information:

Executive Chairman
Michael Boyd
0447 600 888

Company Secretary
Melanie Leydin
0417 663 119

About Jayex Healthcare Limited - www.jayexhealthcare.com.au

Jayex Healthcare is a leading provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service; and
- the *BluePoint*® remote pharmacy prescription processing and dispensing terminal.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

JAYEX HEALTHCARE LIMITED

ABN

15 119 122 477

Quarter ended ("current quarter")

30 SEPTEMBER 2016

Consolidated statement of cash flows	Current quarter	Year to date
	\$A'000	(9 months)
		\$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	2,013	8,400
1.2 Payments for		
(a) research and development	(27)	(156)
(b) product manufacturing and operating costs	(137)	(2,874)
(c) advertising and marketing	(97)	(178)
(d) leased assets	-	(28)
(e) staff costs	(1,093)	(3,379)
(f) administration and corporate costs	(987)	(3,236)
1.3 Dividends received (see note 3)		
1.4 Interest received	-	2
1.5 Interest and other costs of finance paid	-	(4)
1.6 Income taxes paid	(6)	(6)
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(334)	(1,459)

Consolidated statement of cash flows	Current quarter	Year to date (9 months)
	\$A'000	\$A'000
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(4)	(7)
(b) businesses (see item 10)	-	(1,062)
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	(150)
2.6 Net cash from / (used in) investing activities	(4)	(1,219)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	(362)
3.5 Proceeds from borrowings	350	350
3.6 Repayment of borrowings	-	(5)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	350	(17)

Consolidated statement of cash flows		Current quarter	Year to date
		\$A'000	(9 months)
			\$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	1,742	4,637
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(334)	(1,459)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(4)	(1,219)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	350	(17)
4.5	Effect of movement in exchange rates on cash held	(95)	(283)
4.6	Cash and cash equivalents at end of quarter	1,659	1,659

5.	Reconciliation of cash and cash equivalents	Current quarter	Previous quarter
	at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	\$A'000	\$A'000
5.1	Bank balances	1,659	1,742
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,659	1,742

6. Payments to directors of the entity and their associates

- | | Current quarter |
|--|------------------------|
| | \$A'000 |
| 6.1 Aggregate amount of payments to these parties included in item 1.2 | (11) |
| 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3 | - |
| 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2 | |

Director fee payments for the quarter.

7. Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	
Nil	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		
Nil		


9. Estimated cash outflows for next quarter**	\$A'000
9.1 Research and development	41
9.2 Product manufacturing and operating costs	987
9.3 Advertising and marketing	114
9.4 Leased assets	-
9.5 Staff costs	1,052
9.6 Administration and corporate costs	1,202
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	3,396

*** Please note that the above estimated cash outflows for the next quarter do not include inflows of receipts from customers. The cash outflows are estimates only and variable outflows are calculated on forecast revenue for the quarter. Variable outflows will change if actual revenue differs from forecast revenue.*

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	Jayex Technologies Limited	
10.2 Place of incorporation or registration	United Kingdom	
10.3 Consideration for acquisition or disposal	\$9,082,378 Note Business was acquired in December 2015, final payment of \$1,062,000 paid in January 2016	
10.4 Total net assets	\$2,395,000	
10.5 Nature of business	Development and sales of health services workflow hardware and software systems.	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here:
(Company secretary)

Date: 31 October 2016

Print name: Melanie Leydin

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.